← Back to Search

Dopamine D1 Receptor Antagonist

Ecopipam 50mg for Language Disorder

Phase 2 & 3
Waitlist Available
Research Sponsored by Gerald Maguire, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up this scale is completed on visit 1/screening, visit 2/baseline, visit 3/week 2, visit 4/week 4 and visit 5/week 8.
Awards & highlights

Study Summary

The primary objective of this study is to evaluate the efficacy and tolerability of ecopipam in reducing stuttering symptoms. It is hypothesized that ecopipam effectively reduces stuttering symptoms as measured on the SSI-IV total score, the CGI, SSS and OASES.

Eligible Conditions
  • Language Disorder
  • Speech Disorder
  • Stuttering
  • Speech Disorders

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~this scale is completed on visit 1/screening, visit 2/baseline, visit 3/week 2, visit 4/week 4 and visit 5/week 8.
This trial's timeline: 3 weeks for screening, Varies for treatment, and this scale is completed on visit 1/screening, visit 2/baseline, visit 3/week 2, visit 4/week 4 and visit 5/week 8. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in the Stuttering Severity Instrument Version IV (SSI-IV)
Secondary outcome measures
Abnormal Involuntary Movement Scale (AIMS)
Barnes Akathisia Scale (BAS)
Clinical Global Impression Scale-Severity (CGI-S)
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Ecopipam 50mgExperimental Treatment2 Interventions
50mg of ecopipam at bedtime for the first two weeks. If there is deemed improvement by the investigator, the subject will remain on the same dose. If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
Group II: Ecopipam 100mgExperimental Treatment2 Interventions
If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.

Find a Location

Who is running the clinical trial?

Gerald Maguire, MDLead Sponsor
University of California Riverisde School of MedicineUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).
Gerald Maguire, MD 2016. "Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02909088.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top